Lenalidomide Sandoz (Lenalidomide)

Lenalidomide exerts its anti‑tumor activity by binding to cereblon, a component of the CRL4^CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to ubiquitination and proteasomal degradation of the transcription factors Ikaros and Aiolos. The resulting effects include inhibition of angiogenesis, modulation of cytokine production, and enhanced immune‑mediated killing of malignant cells, collectively suppressing tumor growth.

The specific dose of Lenalidomide Sandoz is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and concurrent therapies. Dosage regimens may vary between daily, weekly, or cyclical schedules, and the prescriber determines the appropriate strength, frequency, and duration of treatment. Patients should follow the exact instructions provided on the prescription label.

Lenalidomide is classified as Pregnancy Category X, indicating that it is contraindicated in pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended for breastfeeding mothers, as it can be excreted in milk and may cause adverse effects in the infant.

To request Lenalidomide Sandoz, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials to verify eligibility. After verification, the sales team provides pricing, availability, shipping details—including any temperature‑controlled logistics—and assists with import documentation.

The primary alternative to lenalidomide in many hematologic indications is thalidomide, another immunomodulatory agent. Compared with thalidomide, lenalidomide generally shows a more favorable safety profile, with lower rates of peripheral neuropathy and constipation, while retaining similar anti‑angiogenic and immunomodulatory effects. Both drugs share a risk of thrombosis, so risk‑mitigation strategies are applied for each.

Lenalidomide Sandoz tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the medication in its original blister pack or container to protect it from moisture, light, and excessive heat. Do not store in bathrooms or near kitchen appliances, and keep out of reach of children. Do not freeze the tablets.

Lenalidomide Sandoz is taken orally, usually with a glass of water. The tablets can be swallowed whole and may be taken with or without food, unless the prescribing physician advises otherwise. Patients should adhere to the dosing schedule prescribed, which may involve daily intake for a set number of days followed by a rest period, to maintain therapeutic effectiveness while minimizing toxicity.

The most serious adverse risks include venous thromboembolism, which can manifest as deep‑vein thrombosis or pulmonary embolism, and secondary primary malignancies, where new cancers develop during treatment. Severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, as well as significant liver injury (hepatotoxicity), also require immediate medical attention. Patients should be monitored closely for signs of these events.

Lenalidomide Sandoz is contraindicated in pregnant women and in individuals with known hypersensitivity to lenalidomide or any of the tablet excipients. Patients with uncontrolled active infections, severe renal impairment (creatinine clearance < 30 mL/min) without dose adjustment, or those receiving certain strong CYP3A4 inducers may also be unsuitable candidates. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.